Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline

Giovanna Aparecida Balarini Lima; Evelyn de Oliveira Machado; Cintia Marques Dos Santos Silva; Paulo Niemeyer Filho; Mônica Roberto Gadelha

doi:10.1007/s11102-007-0046-6

Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline

Pituitary. 2008;11(3):287-92. doi: 10.1007/s11102-007-0046-6.

Authors

Giovanna Aparecida Balarini Lima¹, Evelyn de Oliveira Machado, Cintia Marques Dos Santos Silva, Paulo Niemeyer Filho, Mônica Roberto Gadelha

Affiliation

¹ Division of Endocrinology, Clementino Fraga Filho University Hospital/Federal University of Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco, no. 255, Cidade Universitária - Ilha do Fundão, Rio de Janeiro, RJ, Brazil.

PMID: 17570067
DOI: 10.1007/s11102-007-0046-6

Abstract

Pituitary apoplexy is a rare and life-threatening clinical condition caused by hemorrhage and/or infarction of the pituitary gland or adenoma. Although pituitary apoplexy is usually spontaneous, it has been associated with numerous precipitating factors, such as bromocriptine use. However, reports of pituitary apoplexy during cabergoline therapy are scarce. We report three patients with cystic macroprolactinomas who developed pituitary apoplexy during cabergoline treatment.

Publication types

Case Reports

MeSH terms

Adolescent
Adult
Antineoplastic Agents / adverse effects*
Cabergoline
Dopamine Agonists / adverse effects*
Ergolines / adverse effects*
Fatal Outcome
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Pituitary Apoplexy / chemically induced*
Pituitary Apoplexy / pathology
Pituitary Neoplasms / drug therapy*
Pituitary Neoplasms / pathology
Prolactinoma / drug therapy*
Prolactinoma / pathology
Tomography, X-Ray Computed

Substances

Antineoplastic Agents
Dopamine Agonists
Ergolines
Cabergoline